Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a specialty pharmaceutical company based in Vancouver, BC, focused on addressing the global nicotine dependence epidemic through the advancement of cytisinicline. Currently in the late stages of development, the company submitted a New Drug Application to the FDA in June 2025 for cytisinicline as a treatment for smoking cessation in adults.
Cytisinicline has shown promise in clinical trials, demonstrating favorable odds of helping even highly dependent smokers quit, while potentially having fewer side effects compared to existing treatments. With nicotine dependence affecting millions and contributing to substantial healthcare costs, Achieve Life Sciences aims to redefine treatment options for this widespread public health crisis.
Generated from the website
